EUVIMEDEUVIMED entdecken
Crossref

Combined Inhibition of XPO1 and DNA Methylation Exerts Synergistic Effects in DLBCL

Qi Li, Xiaofeng Xue, Si Chen, Xinyun Zhang, Yuchen Zhang, Ruijing Hu, Xinyuan Zhang, Linlin Qin, Menglu Chen, Wenzhuo Zhuang, Bingzong Li iD

Molecular Carcinogenesis · 2025-10 · 64 (10) · 1609-1619

DOI: 10.1002/mc.70014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, online erschienen am 13.07.2025. Verfasst von Qi Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, DNA Methylation, Hydrazines, Receptors, Cytoplasmic and Nuclear. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: The research leading to these results has received funding from National Natural Science Foundation of China (82270211; 82270197; 82470199); Suzhou City Basic….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B‐cell lymphoma (DLBCL) is an aggressive type of non‐Hodgkin lymphoma characterized by high rates of relapse and limited responsiveness to standard chemotherapy. Selinxor, a selective inhibitor of XPO1, exhibited antitumor activity in various cancers. However, clinical trial results revealed that selinexor monotherapy exhibited unsatisfactory efficacy in DLBCL. Our study indicated that XPO1 expression was increased in DLBCL and was correlated with poor outcomes of DLBCL patients. Comprehensive proteomic and transcriptomics analysis showed that selinexor has significant impacts on various biological processes in DLBCL. Furthermore, we explored combination strategies involving selinexor to enhance DLBCL treatment. We examined the combined effects of selinexor with decitabine (DAC) and lenalidomide (LEN), and found that selinexor exhibited a synergistic effect with DAC against DLBCL. Further analysis revealed that DAC exerted a synergistic antitumor effect with selinexor by reversing the DNMT1 expression and DNA methylation alterations induced by selinexor. Overall, these findings provided valuable insights into the global impact of selinexor on DLBCL. The combination therapy of selinexor and DAC emerges as a highly promising strategy for effectively treating DLBCL, holding great potential for clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseDNA MethylationHydrazinesReceptors, Cytoplasmic and NuclearKaryopherinsTriazolesAntineoplastic Combined Chemotherapy ProtocolsHumansExportin 1 ProteinDrug SynergismDecitabineGene Expression Regulation, NeoplasticCell Line, TumorLenalidomideDNA (Cytosine-5-)-Methyltransferase 1Cell ProliferationFemaleMaleXenograft Model Antitumor Assays

Stichwörter der Autor:innen

DNA methylationXPO1combination therapydecitabinediffuse large B‐cell lymphoma

Substanzen

selinexorExportin 1 ProteinHydrazinesReceptors, Cytoplasmic and NuclearKaryopherinsTriazolesDecitabineLenalidomideDNA (Cytosine-5-)-Methyltransferase 1DNMT1 protein, human

Autor:innen und Institutionen

  • Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
  • Suzhou Sano Precision Medicine Ltd., Suzhou, Jiangsu, China.
  • Department of Cell Biology, School of Basic Medical Sciences, Soochow University, Suzhou, Jiangsu, China.

ORCID-Profile: Bingzong Li

Förderung

  • The research leading to these results has received funding from National Natural Science Foundation of China (82270211; 82270197; 82470199); Suzhou City Basic…

Zitieren

APA

Li, Q., Xue, X., Chen, S., Zhang, X., Zhang, Y., Hu, R., Zhang, X., Qin, L., Chen, M., Zhuang, W., & Li, B. (2025). Combined Inhibition of XPO1 and DNA Methylation Exerts Synergistic Effects in DLBCL. Molecular Carcinogenesis, 64(10), 1609-1619. https://doi.org/10.1002/mc.70014

Vancouver

Li Q, Xue X, Chen S, Zhang X, Zhang Y, Hu R, et al. Combined Inhibition of XPO1 and DNA Methylation Exerts Synergistic Effects in DLBCL. Molecular Carcinogenesis. 2025;64(10):1609-1619. doi:10.1002/mc.70014

BibTeX
@article{Li2025,
  author = {Li, Qi and Xue, Xiaofeng and Chen, Si and Zhang, Xinyun and Zhang, Yuchen and Hu, Ruijing and Zhang, Xinyuan and Qin, Linlin and Chen, Menglu and Zhuang, Wenzhuo and Li, Bingzong},
  title = {Combined Inhibition of XPO1 and DNA Methylation Exerts Synergistic Effects in DLBCL},
  journal = {Molecular Carcinogenesis},
  year = {2025},
  volume = {64},
  number = {10},
  pages = {1609--1619},
  doi = {10.1002/mc.70014}
}
Kostenlos starten →